Ligelizumab trumps Xolair in spontaneous urticarial trial
The drug achieved complete control of hives in 51% and 42% of patients, compared with 26% of patients treated with Xolair.
Read More
Tag: dose-finding
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
